Internal Medicine / Cardiovascular Diseases

The Washington University physicians in the Department of Internal Medicine encompass 14 specialty clinical divisions.

Over 270 physicians in the department of medicine treat patients with a wide range of diseases, disorders and conditions.

Text Size: S M L

Home > Physicians Directory > Internal Medicine / Cardiovascular Diseases

Gregory M. Lanza, MD, PhD

Specialty Areas
Cardiovascular Disease
Cardiology

Areas of Clinical Interest
Heart disease, molecular imaging, in vivo molecular imaging, site targeted ultrasound; supervising and interpreting diagnostic tests, such as echocardiograms, stress echocardiograms, treadmill stress test, holter, event and loop monitors

This physician provides professional consultation only.

Major or Recent Publications/Awards

Selected Honors and Awards

Listed in Best Doctors in America, 2008 (Best Doctors, Inc)
Phi Kappa Phi Honor Society
Gamma Sigma Delta Agricultural Honor Society
NIH Research Festival for Outstanding PGY1 Researchers
AHA Fellowship, Missouri Affiliate
Bristol-Myers Squibb Fellowship Award (1997)
Bracco Diagnostics Inc. / SCA & I Fellowship
American College of Cardiology, Searle Career Development Award (2000)

Selected Publications - Books and Book Chapters, Peer-Reviewed Journal Articles

Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM.19F MR imaging and spectroscopy enhance molecular imaging with paramagnetic perfluorocarbon nanoparticles on 1.5T clinical scanners. Invest. Radiol. 2005; (In Press)

Hughes, MS, Marsh, JN, Hall, CS, Fuhrhop, RW, Lacy, EK, Lanza GM, Wickline SA. Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound contrast agent for molecular imaging. J. Acoust. Soc. Am. 2005; 117(2):964-972

Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA. Quantitative magnetic resonance immunohistochemistry with ligand-targeted 19F nanoparticles. Magn Reson Med 2004;52:1255-1262

Robertson, JD, Crane, SB, Wickline, SA, Lanza, GM. Characterization and biodistribution of a novel MRI molecular imaging agent by neutron activation analysis. J Radioanal Nucl Chem. 2005;263(2):511-514

Winter P, Athey P, Kiefer G, Gulyas G, Frank K, Fuhrhop R, Robertson D, Wickline S, Lanza, G. Improved paramagnetic chelate for molecular imaging with MRI. J Magn Magn Mater. 2005; 293:540-545

Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Wickline SA, Lanza GM: MR molecular imaging of melanoma angiogenesis with avB3-Targeted paramagnetic nanoparticles. Magn Reson Med 2005; 53:621-627

Lanza, GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, Wickline SA. MR molecular imaging with nanoparticles: From bench to bedside. J. Nuc. Cardiol 2004; 11:733-743

Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Robertson JD, Lanza GM, Wickline SA: Molecular imaging of angiogenesis in early-stage atherosclerosis with avB3-integrin-targeted nanoparticles. Circulation 2003 108: 2270 - 2274

Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Zhang H, Robertson DJ, Wickline SA, Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 Tesla MRI. Cancer Research 2003;63:5838-5843

Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Zhang H, Robertson DJ, Wickline SA,
Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel avb3-targeted nanoparticle and 1.5 Tesla MRI. Cancer Research 2003;63:5838-5843

Winter PM, Caruthers SD, Yu X, Song SK, Chen J, Miller B, Bulte JWM, Robertson JD, Gaffney PJ, Wickline
SA, Lanza GM. Improved Molecular Imaging Contrast Agent for Detection of Human Thrombus. Mag Reson Med 2003; 50:411-416

Lanza GM, Xin Y, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen LK, Fuhrhop RW, Scherrer
DE, Wickline SA. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002; 106: 2842-2847

Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen J, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA,
Lanza GM. A novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285

Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen J, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA,
Lanza GM. A novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285

Yu X, Song S-K, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000; 44: 867-872

Lanza GM, Lorenz CH, Fischer SE, Scott MJ, Cacheris WP, Kaufman RJ, Gaffney PJ, Wickline SA. Enhanced detection of thrombi with a novel fibrin targeted magnetic resonance imaging agent. Acad Radiol 1998; 5 (Suppl 1): S173 S176

Lanza GM, Trousil RL, Wallace KD, Scott MJ, Miller JG, Eisenberg PR, Gaffney PJ, Wickline SA. In vitro
characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am 1998; 104 (6): 3665-3672

Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94: 3334-3340